# AnchorDx Medical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anchordx-medical-co

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.anchordx.com
- Total disclosed funding: $68M
- Latest round: Series C (Feb 23, 2021)
- Investors on record: 10

## About

AnchorDx Medical Co. Ltd. is a biotechnology company focused on developing innovative diagnostic solutions for the early detection and diagnosis of various cancers, utilizing advanced technologies for improved patient outcomes.Founded in 2015, AnchorDx Medical Co. Ltd. operates out of Guangzhou, China, specializing in cancer diagnostics. The company has not undergone significant strategic pivots since its inception, and there is no mention of subsidiaries. The CEO and founder, Jianbing Fan, has a history in the biotechnology sector. The company has successfully completed a total of 3 funding rounds, with the latest being a Series C funding round in February 2021, raising USD 40.00 mn from OrbiMed Advisors and Yaoming Huiying Investment Management (Suzhou).AnchorDx Medical Co. Ltd. specializes in innovative products designed for the early detection and diagnosis of various cancers. Their core offerings include non-invasive methylation detection kits, such as the UriFind® for urinary tract cancer and the PulmoSeek™ Plus for lung nodules, both leveraging advanced ctDNA methylation high-throughput sequencing technology. The company also provides AI-assisted CT image analysis systems for lung nodules and proprietary software for methylation analysis, catering primarily to healthcare providers and medical institutions across mainland China and potential international markets.AnchorDx Medical Co. Ltd. generates revenue through the sale of its diagnostic products to medical institutions and healthcare providers. The company engages in direct sales, providing its flagship products like the UriFind® and PulmoSeek™ Plus through structured contracts for bulk purchases by hospitals and diagnostic labs. Revenue is generated through one-time sales and recurring orders based on test volumes required by healthcare clients, ensuring ongoing engagement within the medical community.AnchorDx Medical Co. Ltd. plans to leverage the USD 40.00 mn raised during its Series C funding round in February 2021 to enhance its product offerings and expand into new markets. The company is focusing on developing additional diagnostic products aimed at improving early cancer detection, with specific timelines for launch yet to be announced. Additionally, they are targeting expansion into international markets, although specific regions have not been disclosed.

## Funding rounds

- Series C, Feb 23, 2021, $40M — OrbiMed Advisors, Yaoming Huiying Investment Management (Suzhou)
- Series B, Nov 7, 2017, $28M — ARCH Venture Partners, Frontline BioVentures, 6 Dimensions Capital, Guangzhou Kingmed Diagnostics Group Co., Ltd., Marathon Venture Partners, Sijia Jianxin Fund, Wuxi AppTec Group
- Series A, Dec 1, 2015 — NLVC

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Frontline BioVentures (https://capitalatlas.ai/funds/frontline-bioventures) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Guangzhou Kingmed Diagnostics Group Co., Ltd. — Series B
- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Series B
- Sijia Jianxin Fund — Series B
- Wuxi AppTec Group — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Yaoming Huiying Investment Management (Suzhou) — Series C